

Virometix Closes Financing Round

Schlieren, Switzerland (May 19, 2017) – Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector.

Virometix plans to use the new funds to expand its operations and progress its vaccine candidates for infectious and viral diseases and cancer to next inflection points, including the start of a phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent safety and strong efficiency in preclinical models. The financing round was substantially oversubscribed.

Dr Pierre A. Morgon, Chairman of the Board, said: “With this infusion of smart capital from investors experienced in healthcare, and the network of world-class experts supporting the company, Virometix is ideally positioned to leverage its attractive platform with its strong intellectual property position”.

“We are delighted to have received substantial support from our shareholders as well as several new private investors, said Arin Ghasparian, CEO of Virometix, „The new financing will enable us to advance our lead RSV vaccine candidate more rapidly into clinical development, to further define our solution in oncology immunotherapy, and further underpins the attractiveness of our value proposition. “

Emmanuel Savioz, recently appointed CFO, commented “This financing provides the resources we need to reach important value-inflection milestones in 2018 and beyond.”

For further details, please contact:

Dr. Arin Ghasparian, CEO
arin.ghasparian@virometix.com
Tel: +41 43 433 86 60
www.virometix.com

Stefan Mathys, IRF Communications AG
stefan.mathys@irfcom.com
Tel : +41 43 244 81 49
www.irfcom.ch

About Virometix AG

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and cancer. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.

For more information about Virometix AG please visit: <http://www.virometix.com/>